View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 21, 2020updated 23 Nov 2021 4:25am

Inovio reports promising data from its Covid-19 vaccine studies

Inovio Pharmaceuticals has reported promising data from the preclinical studies of its Covid-19 vaccine candidate, IN0-480, in mice and guinea pigs.

Inovio Pharmaceuticals has reported promising data from the preclinical studies of its Covid-19 vaccine candidate, IN0-480, in mice and guinea pigs.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The candidate allegedly generated ‘robust’ neutralising antibodies and T-cell responses against SARS-CoV-2, the novel coronavirus that causes Covid-19.

Inovio and its partners at The Wistar Institute, the University of Texas, Public Health England, Fudan University and Advaccine published these findings in Nature Communications journal.

Inovio Pharmaceuticals R&D senior vice-president and Covid-19 vaccine development team lead Dr Kate Broderick said: “These positive preclinical results from our Covid-19 DNA vaccine (INO-4800) not only highlight the potency of our DNA medicines platform but also build on our previously reported positive Phase I/IIa data from our vaccine against the coronavirus that causes MERS, which demonstrated near-100% seroconversion and neutralisation from a similarly designed vaccine INO-4700.

“The potent neutralising antibody and T cell immune responses generated in multiple animal models are supportive of our currently on-going INO-4800 clinical trials.”

INO-4800 targets the major surface antigen Spike protein of SARS-CoV-2 virus. Three separate neutralisation assays showed the vaccine candidate’s virus neutralising activity and ability to produce antibodies that can block the infection.

Researchers also observed antibodies in the lungs of the vaccinated animals, considered significant for offering protection from the virus.

Also, high levels of Spike-specific T-cell responses were found in animals vaccinated with INO-4800, said to play a key role in mediating protection.

The company expects to report preliminary safety and immune responses data from a Phase I clinical trial next month. Furthermore, a Phase II/III efficacy trial has been planned for launch in July/August, pending regulatory approval

Earlier this month, Inovio signed an agreement with German contract manufacturer Richter-Helm BioLogics for large-scale production of INO-4800.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology